Biostate
Biological1 dose of 50 IU FVIII/kg body weight of Biostate administered intravenously on Day 1 in the PK component, followed by the Efficacy component for continuation of Biostate therapy, as required for a minimum of 50 exposure days.
NCT Number: NCT01229007
The objective of this study is to assess the efficacy and safety of a Von Willebrand Factor/Factor VIII (VWF/FVIII), Biostate, and to investigate the pharmacokinetics of Biostate in children with haemophilia A.
Looking for future studies?
Notify MeUp to 12 year
Male
Interventional
Phase 3
Study site, Homyel, Belarus
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
1 dose of 50 IU FVIII/kg body weight of Biostate administered intravenously on Day 1 in the PK component, followed by the Efficacy component for continuation of Biostate therapy, as required for a minimum of 50 exposure days.
Time frame: Over minimum of 50 exposure days
Time frame: Samples taken prior and then 0.5, 4, 8, 24, and 48 h after the infusion on Day 1
Time frame: Samples taken prior and then 0.5, 4, 8, 24, and 48 h after the infusion on Day 1
Time frame: Samples taken prior and then 0.5, 4, 8, 24, and 48 h after the infusion on Day 1
Time frame: Samples taken prior and then 0.5, 4, 8, 24, and 48 h after the infusion on Day 1
Time frame: Samples taken prior and then 0.5, 4, 8, 24, and 48 h after the infusion on Day 1
Time frame: Samples taken prior and then 0.5, 4, 8, 24, and 48 h after the infusion on Day 1
Time frame: Samples taken prior and then 0.5, 4, 8, 24, and 48 h after the infusion on Day 1
Time frame: Samples taken prior and then 0.5, 4, 8, 24, and 48 h after the infusion on Day 1
Time frame: Samples taken prior and then 0.5, 4, 8, 24, and 48 h after the infusion on Day 1
Time frame: 1 day
Time frame: 1 month
Time frame: 1 year
Time frame: 1 day
Time frame: 1 month
Time frame: 1 year
Time frame: 6 months
Time frame: 6 months
Time frame: 6 months
Time frame: 6 months
Time frame: 6 months
Time frame: Samples taken at screening visit, on day 2, on months 1 and 3, and at final visit
CSL Behring
Industry
A Phase III, Open-Label, Multicentre Study to Evaluate Efficacy, Pharmacokinetics, and Safety of Biostate® in Paediatric Subjects With Haemophilia A
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05147662
Blood Coagulation Disorders, Blood Coagulation Disorders, Inherited
Orlando, Florida, United States
View Trial DetailsNCT06579144
Blood Coagulation Disorders, Blood Coagulation Disorders, Inherited
Sofia, Bulgaria
View Trial DetailsNCT03315455
Blood Coagulation Disorders, Blood Coagulation Disorders, Inherited
Beijing, China
View Trial DetailsNCT04158648
Blood Coagulation Disorders, Blood Coagulation Disorders, Inherited
Los Angeles, California, United States
View Trial Details